ESMO 2024 Prostate Cancer - Results from #40

Viewing 41-58 of 58 articles

ESMO 2024: Radium-223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Patients with Bone Metastatic Castration-Resistant Prostate Cancer: First Results of EORTC-GUCG 1333/PEACE-3

ESMO 2024: Invited Discussant – EORTC-GUCG 1333/PEACE-3

ESMO 2024: First Results from ZZFIRST: a Randomized Phase II Trial of Enzalutamide with or without Talazoparib in Metastatic Hormone-naïve Prostate Cancer

ESMO 2024: Xaluritamig, a STEAP1 x CD3 XmAb 2+1 Immune Therapy, in Patients With Metastatic Castration-Resistant Prostate Cancer: Initial Results From Dose Expansion Cohorts in a Phase 1 Study

ESMO 2024: Symptomatic Skeletal Events, Health-Related Quality of Life and Pain in a Phase 3 Study of [177Lu]Lu-PSMA-617 in Taxane-Naive Patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer: Third Interim Analysis of PSMAfore

ESMO 2024: PSMA PET as a Game Changer for Decision Making?

ESMO 2024: Efficacy of Talazoparib and Enzalutamide in mCRPC Patients Previously Treated with Androgen Receptor Pathway Inhibitors or Docetaxel – Post Hoc Analysis from Both Cohorts in TALAPRO-2 Study

ESMO 2024: Results from the Quick Efficacy Seeking Trial (QuEST1) Arm Combining BN-Brachyury (BNVax) + Bintrafusp Alfa + Nogapendekin Alfa Inbakicept-Pmln (N-803) in Castration-Resistant Prostate Cancer

ESMO 2024: Factors Influencing Clinical and Biological Response in Patients Treated with [177Lu]Lu-PSMA-617 Under France's Early Access Program

ESMO 2024: PSMA-targeted Radioligand Therapy with 131I-LNTH-1095 Plus Enzalutamide versus Enzalutamide Alone in Chemotherapy-naïve Patients Whose Piflufolastat F 18-avid Metastatic Castration-resistant Prostate Cancer Progressed on Abiraterone: ARROW

ESMO 2024: Total and Regional Changes in Body Composition in Metastatic Hormone-Sensitive Prostate Cancer Patients Randomized to Receive Androgen Deprivation + Enzalutamide +/- Zoledronic Acid. the BonEnza Study

ESMO 2024: Association of the Lipid Biomarker, PCPro, and Clinical Outcomes in the ENZAMET Trial (ANZUP 1304)

ESMO 2024: Final Safety and Efficacy Analysis of RaLu: 177Lu-PSMA Therapy in Patients with Prior Radium‑223

ESMO 2024: Prostate Cancer Working Group 4 Preliminary Criteria Using Serial PSMA PET/CT for Response Evaluation: Analysis from the PRINCE Trial

ESMO 2024: Opevesostat (MK-5684/ODM-208), an Oral CYP11A1 Inhibitor, in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Updated CYPIDES Phase 2 Results

ESMO 2024: Novel Therapeutic Approaches for ARPI-resistant Disease

ESMO 2024: Will Theranostics Become Standard of Care?

ESMO 2024: Are Cytotoxics Still the Next Option?

1
2
3